

The 2025 ICD -10-CM codes have been updated and will take effect on October 1, 2024. These updates include 252 new codes, 36 deletions, and 13 revisions. The chart below reflects the newly added codes only.

What does this mean for your organization?

- Ensure your EMR system is updated with the new ICD-10-CM codes.
- Educate not only your providers but also your staff on these changes. Encourage providers to update patient problem lists with the new codes.
- When working on denials, pay close attention to the date of service use the new codes only for dates on or after 10/1/2024. Applying new codes to earlier dates of service can lead to additional denials.

Chapter 1: Certain Infectious and Parasitic Diseases (A00-B99): 0 New Codes			
Chapter 2: Neoplasms (C00-D49) 63 New Codes			
C81.0A - Nodular lymphocyte	C83.5A - Lymphoblastic	C86.21- Enteropathy-type	
predominant Hodgkin	(diffuse) lymphoma, in	(intestinal) T-cell lymphoma,	
lymphoma, in remission	remission	in remission	
C81.1A- Nodular sclerosis	C83.7A - Burkitt lymphoma, in	C86.30 - Subcutaneous	
Hodgkin lymphoma, in	remission	panniculitis-like T-cell	
remission		lymphoma not having	
		achieved remission	
C81.2A - Mixed cellularity	C83.8A - Other non-follicular	C86.31 - Subcutaneous	
Hodgkin lymphoma, in	lymphoma, in remission	panniculitis-like T-cell	
remission		lymphoma, in remission	
C81.3A- Lymphocyte	C83.9A - Non-follicular	C86.40 - Blastic NK-cell	
depleted Hodgkin lymphoma,	(diffuse) lymphoma,	lymphoma not having	
in remission	unspecified, in remission	achieved remission	
C81.4A - Lymphocyte-rich	C84.0A - Mycosis fungoides,	C86.41- Blastic NK-cell	
Hodgkin lymphoma, in remission	in remission	lymphoma, in remission	
C81.7A- Other Hodgkin	C84.1A - Sezary disease, in	C86.50 - Angioimmunoblastic	
lymphoma, in remission	remission	T-cell lymphoma not having achieved remission	
C81.9A- Hodgkin lymphoma,	C84.4A - Peripheral T-cell	C86.51 - Angioimmunoblastic	
unspecified, in remission	lymphoma, not elsewhere classified, in remission	T-cell lymphoma, in remission	
C82.0A- Follicular lymphoma	C84.6A- Anaplastic large cell	C86.60 - Primary cutaneous	
grade I, in remission	lymphoma, ALK -positive, in	CD30-positive T-cell	
	remission	proliferations not having	
		achieved remission	
C82.1A- Follicular lymphoma	C84.7B - Anaplastic large cell	C86.61- Primary cutaneous	
grade II, in remission	lymphoma, ALK -negative, in	CD30-positive T-cell	
	remission	proliferations, in remission	
C82.2A- Follicular lymphoma	C84.AA- Cutaneous T-cell	C88.00 - Waldenstrom	
grade III, unspecified , in	lymphoma, unspecified, in	macroglobulinemia not	
remission	remission	having achieved remission	



C82.3A- Follicular lymphoma grade IIIa, in remission	C84.ZA - Other mature T/NK-cell lymphomas, in remission	C88.01- Waldenstrom macroglobulinemia, in remission
C82.4A- Follicular lymphoma grade IIIb, in remission	C84.9A- Mature T/NK-cell lymphomas, unspecified, in remission	C88.20 - Heavy chain disease not having achieved remission
C82.5A - Diffuse follicle center lymphoma, in remission	C85.1A - Unspecified B -cell lymphoma, in remission	C88.21- Heavy chain disease, in remission
C82.6A- Cutaneous follicle center lymphoma, in remission	C85.2A- Mediastinal (thymic) large B-cell lymphoma, in remission	C88.30 - Immunoproliferative small intestinal disease not having achieved remission
C82.8A- Other types of follicular lymphoma, in remission	C85.8A - Other specified types of non -Hodgkin lymphoma, in remission	C88.31- Immunoproliferative small intestinal disease, in remission
C82.9A- Follicular lymphoma, unspecified, in remission	C85.9A - Non-Hodgkin lymphoma, unspecified, in remission	C88.40 - Extranodal marginal zone B - cell lymphoma of mucosa - associated lymphoid tissue [MALT-lymphoma] not having achieved remission
C83.0A- Small cell B-cell lymphoma, in remission	C86.00 - Extranodal NK/T-cell lymphoma, nasal type not having achieved remission	C88.41- Extranodal marginal zone B -cell lymphoma of mucosa -associated lymphoid tissue [MALT-lymphoma], in remission
C83.1A- Mantle cell lymphoma, in remission	C86.01 - Extranodal NK/T-cell lymphoma, nasal type, in remission	C88.80 - Other malignant immunoproliferative diseases not having achieved remission
C83.390 - Primary central nervous system lymphoma	C86.10 - Hepatosplenic T-cell lymphoma not having achieved remission	C88.81- Other malignant immunoproliferative diseases, in remission
C83.398 - Diffuse large B -cell lymphoma of other extranodal and solid organ sites	C86.11- Hepatosplenic T-cell lymphoma, in remission	C88.90 - Malignant immunoproliferative disease, unspecified not having achieved remission
C83.3A - Diffuse large B -cell lymphoma, in remission	C86.20 - Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission	C88.91 - Malignant immunoproliferativedisease, unspecified, in remission

Chapter 3: Diseases of Blood/Blood-Forming Organs & Disorders Involving Immune Mechanism (D50-D89) 1 New Code

D61.03 - Fanconi anemia



Chapter 4: Endocrine, Nutritio	nal, and Metabolic Diseases (E00	0-E89) 16 New codes
E10.A0 - Type 1 diabetes mellitus, presymptomatic, unspecified	E34.00 - Carcinoid syndrome, unspecified	E66.89 - Other obesity not elsewhere classified
E10.A1 - Type 1 diabetes	E34.01 - Carcinoid heart	E74.820- SLC13A5 Citrate
mellitus, presymptomatic, Stage 1	syndrome	Transporter Disorder
E10.A2 - Type 1 diabetes mellitus, presymptomatic,	E34.09 - Other carcinoid syndrome	E74.829 - Other disorders of citrate metabolism
Stage 2 E16.A1 - Hypoglycemia level 1	E66.811- Obesity, class 1	E88.82 - Obesity due to disruption of MC4R pathway
E16.A2 - Hypoglycemia level 2	E66.812 - Obesity, class 2	,
E16.A3 - Hypoglycemia level 3	E66.813 - Obesity, class 3	
	and Neurodevelopmental Disor	
F50.010 - Anorexia nervosa,	F50.023 - Anorexia nervosa,	F50.810 - Binge eating
restricting type, mild	binge eating/purging type, extreme	disorder, mild
F50.011-Anorexia nervosa,	F50.024 - Anorexia nervosa,	F50.811-Binge eating
restricting type, moderate	binge eating/purging type, in remission	disorder, moderate
F50.012- Anorexia nervosa,	F50.029- Anorexia nervosa,	F50.812- Binge eating
restricting type, severe	binge eating/purging type, unspecified	disorder, severe
F50.013 - Anorexia nervosa,	F50.20 - Bulimia nervosa,	F50.813 - Binge eating
restricting type, extreme	unspecified	disorder, extreme
F50.014 - Anorexia nervosa,	F50.21- Bulimia nervosa,	F50.814 - Binge eating
restricting type, in remission	mild	disorder, in remission
F50.019 - Anorexia nervosa,	F50.22 - Bulimia nervosa,	F50.819 - Binge eating
restricting type, unspecified F50.020 - Anorexia nervosa,	moderate F50.23- Bulimia nervosa,	disorder, unspecified F50.83 - Pica in adults
binge eating/purging type, mild	severe	F30.03- FICA III addits
F50.021- Anorexia nervosa,	F50.24- Bulimia nervosa,	F50.84 - Rumination disorder
binge eating/purging type, moderate	extreme	in adults
F50.022- Anorexia nervosa,	F50.25 - Bulimia nervosa, in	
binge eating/purging type,	remission	
severe		
Chantor 6. Disassa of the Na	ryous System (COO, COO), 7No	codos
-	rvous System (G00 - G99): 7 New	
G40.841 - KCNQ2-related epilepsy, not intractable, with	G40.844 - KCNQ2-related epilepsy, intractable, without	G93.45- Developmental and epileptic encephalopathy
status epilepticus	status epilepticus	ерперис епсернаюранту



	T		
G40.842 - KCNQ2-related	G90.81 - Serotonin syndrome		
epilepsy, not intractable,			
withoutstatus epilepticus			
G40.843 - KCNQ2-related	G90.89 - Other disorders of		
epilepsy, intractable, with	autonomic nervous system		
status epilepticus			
Chapter 7: Diseases of the Eye a	nd Adnexa (H00-	H59) 0 New code	es es
Chapter 8: Diseases of the Ear a	nd Mastoid Proce	ss (H60-H95) 0 N	ew codes
Chapter 9: Diseases of the Circ	ulatory System (100-100) / Now C	odes.
126.03 - Cement embolism of pu			bolism of pulmonary artery
artery with acute cor pulmonal	•	with acute cor	The state of the s
126.95 - Cement embolism of pu			bolism of pulmonary artery
artery without acute cor pulmo	,	without acute	• • • • • • • • • • • • • • • • • • • •
artery without acute cor pullio	riale	Without acute (coi pulliforiale
Chapter 10: Diseases of the Re	cniratory Sycton	2/100 -100\ 7 No	w codos
J34.8200 - Internal nasal	J34.8210 - Exte		J34.829 - Nasal valve
valve collapse, unspecified J34.8201- Internal nasal	valve collapse, unspecified		collapse, unspecified
	J34.8211- External nasal		
valve collapse, static	valve collapse, static		
J34.8202- Internal nasal	J34.8212 - External nasal		
valve collapse, dynamic	valve collapse, dynamic		
Chapter 11: Diseases of the Di	rective System (K00-K95\27 Ne	w Codes
K60.30-Anal fistula,			K60.50-Anorectal fistula
unspecified	K60.40 - Rectal fistula, unspecified		unspecified
K60.311-Anal fistula, simple,	K60.411- Rectal fistula,		K60.511-Anorectal fistula,
initial	simple, initial		simple, initial
K60.312-Anal fistula, simple,	K60.412- Rectal fistula,		K60.512-Anorectal fistula,
persistent	simple, persistent		simple, persistent
K60.313-Anal fistula, simple,	K60.413 - Rectal fistula,		K60.513-Anorectal fistula,
recurrent	,		simple, recurrent
K60.319-Anal fistula, simple,	simple, recurrent		K60.519-Anorectal fistula,
unspecified	K60.419 - Rectal fistula,		simple, unspecified
K60.321-Anal fistula,	simple, unspecified		K60.521-Anorectal fistula,
complex, initial	K60.421 - Rectal fistula,		complex, initial
K60.322-Anal fistula,	complex, initial		K60.522-Anorectal fistula,
	K60.422 - Rectal fistula,		
complex, persistent	complex, persistent K60.423- Rectal fistula,		complex, persistent
K60.323-Anal fistula,		•	K60.523-Anorectal fistula,
complex, recurrent	complex, recur		complex, recurrent
K60.329-Anal fistula,	K60.429 - Rectal fistula,		K60.529-Anorectal fistula,
complex, unspecified	complex, unspe	ciileu	complex, unspecified



Chapter 12: Diseases of the Skin and Subcutaneous Tissue (L00 - L99) 8 New Codes			
L29.81- Cholestatic pruritus	L66.11- Classic lichen planopilaris	L66.81 - Central centrifugal cicatricial alopecia	
L29.89 - Other pruritus	L66.12 - Frontal fibrosing alopecia	L66.89 - Other cicatricial alopecia	
L66.10 - Lichen planopilaris, unspecified	L66.19 - Other lichen planopilaris		
	(MOO MOO) OO M		
M51.360-Other intervertebral	ystem (M00-M99) 33 New codes	M45 051 Upapasified	
disc degeneration, lumbar	M65.912-Unspecified synovitis and tenosynovitis,	M65.951-Unspecified synovitis and tenosynovitis,	
region with discogenic back	left shoulder	right thigh	
pain only	leit silouluei	rigiit tiligii	
M51.361-Other intervertebral	M65.919-Unspecified	M65.952-Unspecified	
disc degeneration, lumbar	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
region with lower extremity	unspecified shoulder	left thigh	
pain only			
M51.362-Other intervertebral	M65.921-Unspecified	M65.959-Unspecified	
disc degeneration, lumbar	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
region with discogenic back	right upper arm	unspecified thigh	
pain and lower extremity pain			
M51.369-Other intervertebral	M65.922-Unspecified	M65.961-Unspecified	
disc degeneration, lumbar	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
region without mention of	left upper arm	right lower leg	
lumbar back pain or lower extremity pain			
M51.370-Other intervertebral	M65.929-Unspecified	M65.962-Unspecified	
disc degeneration,	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
lumbosacral region with	unspecified upper arm	left lower leg	
discogenic back pain only	111		
M51.371-Other intervertebral	M65.931 - Unspecified	M65.969-Unspecified	
disc degeneration,	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
lumbosacral region with lower	right forearm	unspecified lower leg	
extremity pain only			
M51.372-Other intervertebral	<u>-</u>	M65.971-Unspecified	
disc degeneration,	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
lumbosacral region with	left forearm	right ankle and foot	
discogenic back pain and lower extremity pain			
M51.379-Other intervertebral	M65.939-Unspecified	M65.972-Unspecified	
disc degeneration,	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
lumbosacral region without	unspecified forearm	left ankle and foot	
mention of lumbar back pain			
or lower extremity pain			
M62.85 - Dysfunction of the	M65.941-Unspecified	M65.979-Unspecified	
multifidus muscles, lumbar	synovitis and tenosynovitis,	synovitis and tenosynovitis,	
region	right hand	unspecified ankle and foot	



M65.90-Unspecified	M65.942-Unspecified		M65.98-Unspecified
synovitis and tenosynovitis,	synovitis and tenosynovitis,		synovitis and tenosynovitis,
unspecified site	left hand		other site
M65.911-Unspecified	M65.949-Unspecified		M65.99-Unspecified
synovitis and tenosynovitis,	synovitis and te		synovitis and tenosynovitis,
right shoulder	unspecified han	nd	multiple sites
Chapter 14: Disease of Genitou	rinary System (N0	0-N99) 0 New co	odes
Chapter 15: Pregnancy, Childbin	rth and the Puerpe	erium (000 -09A) O New codes
Chapter 16: Certain Conditions	Originating in the	Perinatal Period	(P00-P96) 0 New Codes
Chapter 17: Congenital Malforn	nations, Deformat	ions, and Chrom	osomal Abnormalities (Q00-Q99)
4 New Codes			
Q23.81 - Bicuspid aortic valve		Q23.88 - Other aortic and mitr	congenital malformations of al valves
Q23.82- Congenital mitral valv	e cleft leaflet	Q87.86 - Kleefs	
Chapter 18: Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00-R99) 1 New Code R41.85			
Chapter 19: Injury and Poisoni	ng (SOO -T99) 30 I	New codes	
T45.AX1A - Poisoning by	T45.AX4D - Poi		T81.320S - Disruption or
immune checkpoint inhibitors	immune checkp		dehiscence of gastrointestinal
and immunostimulant drugs,	and immunostimulant drugs,		tract anastomosis, repair, or
accidental (unintentional),	undetermined, subsequent		closure, sequela
initial encounter	encounter	0.000040.000	3,334,3,434
T45.AX1D - Poisoning by	T45.AX4S - Poi	soning by	T81.321A - Disruption or
immune checkpoint inhibitors	immune checkp		dehiscence of closure of
and immunostimulant drugs,	and immunostir		internal operation (surgical)
accidental (unintentional),	undetermined,	•	wound of abdominal wall
subsequent encounter		·	muscle or fascia, initial
			encounter
T45.AX1S - Poisoning by	T45.AX5A - Adverse effect of		T81.321D - Disruption or
immune checkpoint inhibitors	immune checkpoint inhibitors		dehiscence of closure of
and immunostimulant drugs,	•		internal operation (surgical)
accidental (unintentional),	initial encounte	er	wound of abdominal wall
sequela			muscle or fascia, subsequent
			encounter
T45.AX2A - Poisoning by	T45.AX5D- Adv		T81.321S - Disruption or
immune checkpoint inhibitors	immune checkp		dehiscence of closure of
and immunostimulant drugs,	and immunostir	_	internal operation (surgical)
intentional self-harm, initial	subsequent end	counter	wound of abdominal wall
encounter			muscle or fascia, sequela



T45.AX2D - Poisoning by	T45.AX5S - Adverse effect of	T81.328A - Disruption or
immune checkpoint inhibitors	immune checkpoint inhibitors	dehiscence of closure of
and immunostimulant drugs,	and immunostimulant drugs,	other specified internal
intentional self-harm,	sequela	operation (surgical) wound,
subsequent encounter		initial encounter
T45.AX2S - Poisoning by	T45.AX6A - Underdosing of	T81.328D - Disruption or
immune checkpoint inhibitors	immune checkpoint inhibitors	dehiscence of closure of
and immunostimulant drugs,	and immunostimulant drugs,	other specified internal
intentional self-harm, sequela	initial encounter	operation (surgical) wound,
		subsequent encounter
T45.AX3A - Poisoning by	T45.AX6D - Underdosing of	T81.328S - Disruption or
immune checkpoint inhibitors	immune checkpoint inhibitors	dehiscence of closure of
and immunostimulant drugs,	and immunostimulant drugs,	other specified internal
assault, initial encounter	subsequent encounter	operation (surgical) wound,
		sequela
T45.AX3D - Poisoning by	T45.AX6S - Underdosing of	T81.329A - Deep disruption or
immune checkpoint inhibitors	immune checkpoint inhibitors	dehiscence of operation
and immunostimulant drugs,	and immunostimulant drugs,	wound, unspecified, initial
assault, subsequent	sequela	encounter
encounter		
T45.AX3S - Poisoning by	T81.320A - Disruption or	T81.329D - Deep disruption or
immune checkpoint inhibitors	dehiscence of gastrointestinal	dehiscence of operation
and immunostimulant drugs,	træt anastomosis, repair, or	wound, unspecified,
assault, sequela	closure, initial encounter	subsequent encounter
T45.AX4A - Poisoning by	T81.320D - Disruption or	T81.329S - Deep disruption or
immune checkpoint inhibitors	dehiscence of gastrointestinal	dehiscence of operation
and immunostimulant drugs,	tract anastomosis, repair, or	wound, unspecified, sequela
undetermined, initial	closure, subsequent	
encounter	encounter	
Chapter 20: External Causes o	f Morbidity (V00-Y99) 0New Coo	les
		(======================================
	g Health Status and Contact with	n Health Services (Z0025-Z99)
New Codes	747 404 11	7/05/ 8 1
Z15.1 - Genetic susceptibility	Z17.421 - Hormone receptor	Z68.56 - Body mass index
to epilepsy and	negative with human	[BMI] pediatric, greater than
neurodevelopmental	epidermal growth factor	or equal to 140% of the 95th
disorders	receptor 2 negative status	percentile for age
Z15.2 - Genetic susceptibility	Z51.A - Encounter for sepsis	Z83.72 - Family history of
		familial adenomatous
to obesity	aftercare	
·		polyposis
Z17.21 - Progesterone	Z59.71- Insufficient health	polyposis Z86.0100 - Personal history of
Z17.21 - Progesterone receptor positive status	Z59.71- Insufficient health insurance coverage	polyposis Z86.0100 - Personal history of colon polyps, unspecified
Z17.21 - Progesterone receptor positive status Z17.22 - Progesterone	Z59.71- Insufficient health insurance coverage Z59.72- Insufficient welfare	polyposis Z86.0100 - Personal history of colon polyps, unspecified Z86.0101 - Personal history of
Z17.21- Progesterone receptor positive status	Z59.71- Insufficient health insurance coverage	polyposis Z86.0100 - Personal history of colon polyps, unspecified



Z17.31 - Human epidermal growth factor receptor 2 positive status	Z67.A1 - Duffy null	Z86.0102 - Personal history of hyperplastic colon polyps
Z17.32 - Human epidermal growth factor receptor 2 negative status	Z67.A2 - Duffy a positive	Z86.0109 - Personal history of other colon polyps
Z17.410 - Hormone receptor positive with human epidermal growth factor receptor 2 positive status	Z67.A3 - Duffy b positive	Z92.26 - Personal history of immune check point inhibitor therapy
Z17.411- Hormone receptor positive with human epidermal growth factor receptor 2 negative status	Z67.A4 - Duffy a and b positive	
Z17.420 - Hormone receptor negative with human epidermal growth factor receptor 2 positive status	Z68.55-Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age	

For more information, fill out this **brief form**, and we will get back to you.